acute respiratory distress syndrome ards

52
Acute Respiratory Distress Syndrome (ARDS) Dr. Prasad Gaikwad Guide- Dr. R.S.Khot Dept of internal Medicine IGGMC, Nagpur

Upload: drpragaikwad1988

Post on 11-Apr-2017

870 views

Category:

Education


0 download

TRANSCRIPT

Page 1: Acute Respiratory Distress Syndrome ARDS

Acute Respiratory Distress Syndrome (ARDS)

Dr. Prasad GaikwadGuide- Dr. R.S.Khot

Dept of internal MedicineIGGMC, Nagpur

Page 2: Acute Respiratory Distress Syndrome ARDS

ARDS

• Definition• Etiology • Clinical course and Pathophysiology• Clinical features• Differential diagnosis• Diagnosis• Treatment• Newer modalities- evidence based medicine

Page 3: Acute Respiratory Distress Syndrome ARDS

• 1st described 1967 (Ashbaugh et al)• Incidence 1.5 -7.5/ 100000 population• 28 day mortality 25 – 44%1

Page 4: Acute Respiratory Distress Syndrome ARDS

Other names

• Adult hyaline-membrane disease• Adult respiratory insufficiency syndrome• High output respiratory failure• Congestive atelectasis• Hemorrhagic lung syndrome• Stiff-lung syndrome• Shock lung• White lung

Page 5: Acute Respiratory Distress Syndrome ARDS

Definition

• Clinical syndrome of severe dyspnoea of rapid onset, hypoxemia and diffuse pulmonary infiltrates with absence of left atrial hypertension leading to respiratory failure.

• ALI is less severe form but may evolve into ARDS• ALI Po2/Fio2 ratio <300 mmHg.• ARDS Po2/Fio2 ratio <200 mmHg.

Page 6: Acute Respiratory Distress Syndrome ARDS

• Berlin definition of ARDS

Page 7: Acute Respiratory Distress Syndrome ARDS

Clinical disorders associated with ARDS

Direct lung injury 1)pneumonia 2)aspiration of gastric contents 3)pulmonary contusion 4)near drowning 5)toxic inhalation injury

Indirect lung injury 1) Sepsis 2)Severe trauma 3)Multiple fractures 4) Multiple blood transfusion 5)Pancreatitis 6) Cardiopulmonary bypass

Page 8: Acute Respiratory Distress Syndrome ARDS

Clinical course and Pathophysiology

• 3 phases 1)Exudative phase- hyaline membrane- 0 to 7 day 2) Proliferative phase- interstitial inflammation- 7 to 21 day 3) Fibrotic phase- fibrosis- after 21 days

Page 9: Acute Respiratory Distress Syndrome ARDS

Pathophysiology during exudative phase

Direct or indirect injury to the alveolus causes alveolar macrophages to release pro-inflammatory cytokines

↓ Cytokines attract neutrophils into the alveolus and interstitum, where they damage the alveolar-capillary membrane (ACM).

↓ . ACM integrity is lost, interstitial and alveolus fills with proteinaceous fluid, surfactant can no longer support alveolus

Page 10: Acute Respiratory Distress Syndrome ARDS

• Exudative Phase • Neutrophilic Infiltrate• Alveolar Haemorrhage• Proteinaceous Pulmonary Oedema• Cytokines (TNF, IL1,8)

» ↑ Inflammation» ↑ Oxidative Stress and Protease Activity» ↓ Surfactant Activity» Atelectasis

Elastase- induced capillary and alveolar damage3

↑ Alveolar flooding ↓ Fluid clearance

Page 11: Acute Respiratory Distress Syndrome ARDS

Proliferative phase

lasts around 7-21 days initiation of lung repair organisation of alveolar exudates shift from PMN to lymphocyte rich infiltrate Type II pneumocyte

Synthesize surfactant proliferate differentiate into Type I cells reline alveolar walls

Fibroblast proliferation interstitial/alveolar fibrosis

Page 12: Acute Respiratory Distress Syndrome ARDS

Fibrotic phase

Extensive alveolar duct and interstitial fibrosis.Emphysema like changes with bullae formation.Fibrosis may result into progressive vascular occlusion and pulmonary hypertension.

Page 13: Acute Respiratory Distress Syndrome ARDS

Consequences of lung injury include:

1)Impaired gas exchange-due to hyaline membrane V/Q mismatch Related to filling of alveoli Shunting causes hypoxemia

Increased dead space Related to capillary dead space and V/Q mismatch Impairs carbon dioxide elimination Results in high minute ventilation

2)Decreased compliance- more in dependent lung portions Hallmark of ARDS Consequence of the stiffness of poorly or nonaerated lung Fluid filled lung becomes stiff/boggy Requires increased pressure to deliver Vt

Page 14: Acute Respiratory Distress Syndrome ARDS

3) Increased pulmonary arterial pressure Occurs in up to 25% of ARDS patients Results from hypoxic vasoconstriction Positive airway pressure causing vascular compression Can result in right ventricular failure

Page 15: Acute Respiratory Distress Syndrome ARDS

Clinical featuresSymptoms • Acute onset exertional dyspnoea leading to dyspnoea at rest.• Tachypnea • Anxiety• Agitation • Increased work of breathingPhysical examination• Tachypnea • Tachycardia• Increased FiO2 to maintain saturation• May be febrile of hypothermic• Cold extremities• Bilateral crepitation• Manifestation of underlying cause• Cardiogenic pulmonary edema to be ruled out

Page 16: Acute Respiratory Distress Syndrome ARDS

Differential diagnosis

• Cardiogenic pulmonary edema• Diffuse pneumonia• Alveolar hemorrhage• Acute interstitial pneumonitis• Hypersensitive pneumonitis• Neurogenic pulmonary edema

Page 17: Acute Respiratory Distress Syndrome ARDS

Diagnosis

Mainly clinical-no specific diagnostic testsLaboratory testsDiagnostic imagingHemodynamic monitoringBronchoscopy

Page 18: Acute Respiratory Distress Syndrome ARDS

Lab tests

• ABG analysis PaO2/FIO2 ratio is less than 200. Respiratory acidosis later on metabolic acidosis• To exclude cardiogenic pulmonary edema- B-type natriuretic peptide (BNP) value <100 pg/mL Echocardiogram• Hematological- either leukocytosis or leucopenia• Renal- (ATN) often ensues in the course of ARDS• Hepatic-Liver function abnormalities may be noted in either a

pattern of hepatocellular injury

Page 19: Acute Respiratory Distress Syndrome ARDS

ABG in ARDS

Initial stages PaO2 < 60 mmHg PaCO2 < 35 mmHg pH- may normal or increased showing respiratory alkalosis P/F ratio <200Late stages PaO2 more falling despite oxygen therapy PaCO2 >45 mmHg showing respiratory acidosis Serum bicarbonates < 22 mEq/L showing metabolic acidosis P/F ratio <200

Page 20: Acute Respiratory Distress Syndrome ARDS

Radiological –chest x-ray

Shows bilateral alveolar and interstitial opacities involving atleast three-quarters of lung fields.Difficult to d/w from cardiogenic pulmonary edema.

Page 21: Acute Respiratory Distress Syndrome ARDS

Initial patchy peripheral distribution but later on progresses to ground glass alveolar opacities.

Page 22: Acute Respiratory Distress Syndrome ARDS

Radiological CT thorax

heterogeneity of alveolar involvement is apparent on CT scan

Page 23: Acute Respiratory Distress Syndrome ARDS

Invasive Hemodynamic Monitoring

• Hemodynamic monitoring with a pulmonary artery (Swan-Ganz) catheter may be helpful in selected cases for distinguishing cardiogenic from noncardiogenic pulmonary edema.

• This allows measurement of RA pressure, RV pressure, PA pressure and pulmonary artery occlusion pressure (PAOP).

• A PAOP lower than 18 mm Hg is usually consistent with noncardiogenic pulmonary edema.

• However their use is controversial.• One large retrospective cohort study of ICU showed that patients

with pulmonary artery catheters had an increased mortality rate, hospital cost, and length of stay.

• Hence not indicated for routine patients.

Page 24: Acute Respiratory Distress Syndrome ARDS

Bronchoscopy • May be considered to evaluate the possibility of infection,

alveolar hemorrhage, or acute eosinophilic pneumonia in patients acutely ill with bilateral pulmonary infiltrates

• >10000 organisms/mL is significant for diagnosis of ARDS for patients who are not treated with antibiotics.

• Presence of neutrophils in the BAL fluid with the presence of intracellular organisms is helpful in diagnosis of ARDS

• Analysis of the types of cells present in the BAL fluid may be helpful in the differential diagnosis of patients with ARDS.

>20% eosinophils-acute eosinophilic pneumonia high proportion of lymphocytes may be observed in acute hypersensitivity pneumonitis, sarcoidosis, or bronchiolitis obliterans-organizing pneumonia (BOOP)

Page 25: Acute Respiratory Distress Syndrome ARDS

Management of ARDS

• Treat the underlying cause.• Conservative fluid management.• Non invasive ventilation.• Mechanical ventilation.• Other modalities.

Page 26: Acute Respiratory Distress Syndrome ARDS

Treating underlying cause

The underlying cause may be treated with broad spectrum antibiotic as with patients having pneumonia, pancreatitis and severe sepsisSurgical intervention if needed should be carried out

Page 27: Acute Respiratory Distress Syndrome ARDS

Fluid management

• Aggressive attempts to reduce left atrial filling pressure-will help in minimizing pulmonary edema and improved arterial oxygenation

• Can be achieved by fluid restriction and diuresis• Approach limited by hypotension Hypoperfusion of end organs Secondary ARDS due to remote infection and inflammation

Page 28: Acute Respiratory Distress Syndrome ARDS

Non-invasive ventilation

• Continuous CPAP or Non invasive ventilation using BiPAP mask may be beneficial in early course of disease.

• But often patients unable to maintain saturation , get drowsy, develop altered sensorium

• Very little data available for its use • Invasive mechanical ventilation is mandatory

Page 29: Acute Respiratory Distress Syndrome ARDS

Mechanical ventilation

• Goals of mechanical ventilation Low tidal volume ventilation to avoid volutrauma Maintain O2 saturation between 85-90% Minimizing FiO2 < 0.65 within first 48 hrs of ventilation Optimum PEEP Minimal plateau pressures

Page 30: Acute Respiratory Distress Syndrome ARDS

Mechanical ventilationLow Tidal Volume Ventilation

• ONLY RECOMMENDED BEST THERAPEUTIC APPROACH OVER 4 DECADES

• When compared to larger tidal volumes, Vt of 6ml/kg of ideal body weight:• Decreased mortality• Increased number of ventilator free days• Decreased extrapulmonary organ failure

• Mortality is decreased in the low tidal volume group despite these patients having:• Worse oxygenation• Increased pCO2 (permissive hypercapnia)• Lower pH

Page 31: Acute Respiratory Distress Syndrome ARDS

• ARDS affects the lung in a heterogeneous fashion• Normal alveoli- can cope up with normal or higher vt • Injured alveoli -can potentially participate in gas exchange,

susceptible to damage from opening and closing of higher vt

• Damaged alveoli-filled with fluid, do not participate in gas exchange

• High tidal volumes• Overdistention of alveoli• Local inflammatory response resulting in systemic

inflammation with release of inflammatory cytokines• Recommended 4-6ml/kg

Page 32: Acute Respiratory Distress Syndrome ARDS

Optimum PEEP

• Empirically set to a level that it will minimize FiO2 and maximize PaO2.

• On most modern mechanical ventilators it is possible to set static pressure –volume curves.

• Titration of PEEP to the lower inflection point on pressure –volume curve- keeps lungs open, improves oxygenation, minimizes barotrauma.

• Optimum PEEP for most of patients ranges from 12-15 mmHg

Page 33: Acute Respiratory Distress Syndrome ARDS

PEEP

Page 34: Acute Respiratory Distress Syndrome ARDS

Inverse ratio ventilation

I:E ratio > 1:1Inspiratory time lengthened and expiratory time shortened.Same strategy like increasing ventilator prescribed PEEPMay help to keep FiO2 < 0.6 to avoid oxygen induced toxicity

Long term survival benefit is questionable.

Page 35: Acute Respiratory Distress Syndrome ARDS

Airway Pressures in ARDS

• Plateau pressure is most predictive of lung injury• Goal- plateau pressure < 30, the lower plateau pressure the

better is outcome• Decreases alveolar over-distention and reduces risk of lung

strain• Adjust tidal volume to ensure plateau pressure at goal• It may be permissible to have plateau pressure > 30 in some

cases• Obesity• Pregnancy• Ascites

Page 36: Acute Respiratory Distress Syndrome ARDS

• Assess cause of high Plateau Pressures• Always represents some pathology:

– heart failure– Pneumothorax– Auto-peeping– Mucus Plug– Right main stem intubation– Chest wall fat / Obesity

Page 37: Acute Respiratory Distress Syndrome ARDS

Permissive hypercapnia

• It’s a consequence of low Vt ventilation.• Patients often develop hypercapnia and respiratory acidosis.• Small studies in favour of PaCO2 levels as high as 375mmHg

and pH as low as 6.6• However recent meta-analysis suggest that PaCO2 of 60-70

mmHg and pH range 7.2-7.25 are sufficient to avoid volutrauma.

• Troublesome part- patients often develop hyperventilation and ventilator asynchrony; needs managed with neuromuscular blockade.

Page 38: Acute Respiratory Distress Syndrome ARDS

Ventilatory parametersFirst stage1)Calculate patient’s predicted body weight:

• Men (kg) = 50 + 2.3(height in inches – 60)• Females (kg) = 45.5 + 2.3(height in inches – 60)

2)Set Vt = predicted body weight x 8 mL/kg3)Add PEEP of 5-7 cm H2O4)Reduce Vt every 2hrs by 1 mL/kg till 6mL/kg PBWSecond stageNow set target plateau pressure <30 cmH2O by adjusting Vt till 4mL/kgThird stage1)Target pH= 7.30-7.452)If pH <7.30 then adjust RR till 35br per minute

Page 39: Acute Respiratory Distress Syndrome ARDS

Weaning

• Daily CPAP breathing trial– FiO2 <.40 and PEEP <8– Patient has acceptable spontaneous breathing efforts– No vasopressor requirements,

• Pressure support weaning– PEEP 5, PS at 5cm H2O if RR <25– If not tolerated, ↑RR, ↓Vt – return to A/C

• Unassisted breathing– T-piece, trach collar– Assess for 30minutes-2 hours

Page 40: Acute Respiratory Distress Syndrome ARDS

Weaning

• Tolerating Breathing Trial?– SpO2 ≥90– Spontaneous Vt ≥4ml/kg PBW– RR ≤35– pH ≥7.3– Pass Spontaneous Awakening Trial (SAT)– No Respiratory Distress ( 2 or more)

• HR < 120% baseline• No Accessory muscle use• No Abdominal Paradox• No Diaphoresis• No Marked Dyspnea

– If tolerated, consider extubation

Page 41: Acute Respiratory Distress Syndrome ARDS

Other modalities

• Prone position ventilation• High frequency ventilation• Partial liquid ventilation• Extracorporeal membrane oxygenation(ECMO)• Systemic glucocorticoids• Surfactant replacement• Inhaled nitric oxide

Page 42: Acute Respiratory Distress Syndrome ARDS

• Prone position ventilation• Redistribution of blood & ventilation to least affected

areas of lung• Secretion clearance• Shifts mediastinum anteriorly – assists recruitment of

atelectatic areas• ? reduce lung injury• Reduced lung compression by abdominal contents

Page 43: Acute Respiratory Distress Syndrome ARDS

Hypothesis: Early application of prone positioning would improve survival in patients with severe ARDS.

Conclusion: Early application of prolonged prone positioning significantly decreased 28 day and 90 mortality in patients with severe ARDS.

Page 44: Acute Respiratory Distress Syndrome ARDS

• High frequency oscillation ventilation(HFOV) uses small tidal volumes(1-2 mL/kg) at a very fast rate(5-20 cycles per second) Had been useful in animal studies Lack proven benefit in human. Instead hazardous

Page 45: Acute Respiratory Distress Syndrome ARDS

-Randomized control trial, stopped with 548 of 1200 patients-Found early initiation of HFOV does not reduce hospital mortality and may increase hospital mortality

Page 46: Acute Respiratory Distress Syndrome ARDS

• Extracorporeal membrane oxygenation(ECMO) had proven benefit for neonatal respiratory syndrome but not for ARDS

• Partial liquid ventilation uses high density , inert liquid of per-fluorocarbon which solubilizes oxygen and carbon dioxide; thought to improve oxygenation.No clear benefit on survival

Page 47: Acute Respiratory Distress Syndrome ARDS

Inhaled nitric oxide can be of help in early course of treatment to improve oxygenation but no improved survival benefit

Glucocorticoids To suppress inflammation in early ARDS did not have any have any evidence based recommendation Instead deleterious effect on pulmonary inflammation

Page 48: Acute Respiratory Distress Syndrome ARDS

• Enrolled 282 patients with aerosolized albuterol and saline placebo with primary outcome as ventilator free days.

• Conclusion -aerosolized albuterol does not improve clinical outcomes in patients with ALI. Routine use of b2-agonist therapy in mechanically ventilated patients with ALI can not be recommended

Page 49: Acute Respiratory Distress Syndrome ARDS

Evidence –based recommendations for ARDS therapies

Treatment Recommendation

Low tidal volume A

Minimize left atrial filling pressure

B

High PEEP C

Prone position C

ECMO C

High frequency ventilation D

glucocorticoids D

Surfactant replacement and inhaled nitric oxide

D

A- recommended on evidence based RCTsB- recommended based on supportive but limited clinical trialsC- recommended only as alternative therapyD- not recommended as evidence is against efficacy

Page 50: Acute Respiratory Distress Syndrome ARDS

Prognosis

• Mortality ranges from 26-44%• Mostly attributable to underlying cause of ARDS• Age is most important predictor of mortality• Other predictors- presence of liver damage, alcohol abuse,

APACHE III score, presence of kidney injury• Patients >60yrs have threefold mortality than <60yrs• Patients having direct lung injury have twofold more mortality

than indirect lung injury.

Page 51: Acute Respiratory Distress Syndrome ARDS

Sequelae

• Patients usually recover complete lung functions within 6 months.

• One third of Survivors have normal spirometry and diffusion capacities after 6 months.

• Significant rates of depression and post traumatic stress disorder amongst survivors.

Page 52: Acute Respiratory Distress Syndrome ARDS

Thank you